Table 3.
Antibacterial Activities of 13–15 against S. aureus and E. faecalis
| MIC (μg/mL)
|
||||||
|---|---|---|---|---|---|---|
| compound or control agent | S. aureus 8325-4 (MSSA) | S. aureus ATCC 49951 (MSSA) | S. aureus ATCC 33591 (MRSA) | S. aureus Mu3a (MRSA) | E. faecalis ATCC 19433 (VSE) | E. faecalis ATCC 51575 (VRE) |
| 13 | 1.0 | 1.0 | 1.0 | 1.0 | 4.0 | 4.0 |
| 14 | 8.0 | 8.0 | 16.0 | 8.0 | 32.0 | 64.0 |
| 15 | 64.0 | 32.0 | 64.0 | 32.0 | >64.0 | >64.0 |
| oxacillin | 0.063 | 0.25 | >64.0 | >64.0 | 8.0 | 64.0 |
| clindamycin | 0.031 | 0.063 | >64.0 | >64.0 | 2.0 | >64.0 |
| erythromycin | 0.125 | 0.25 | >64.0 | >64.0 | 1.0 | >64.0 |
| vancomycin | 0.5 | 0.5 | 2.0 | 2.0 | 1.0 | >64.0 |
a
Mu3 is a clinical MRSA isolate also identified as being a hetero-glycopeptide-intermediate S. aureus (hetero-GISA) strain.